Ireland

001-35299

98-1007018

(State or other jurisdiction

(Commission

(IRS Employer

of incorporation)

File Number)

Identification No.)

Connaught House, 1 Burlington Road

Dublin 4, Ireland

(Address of principal executive offices)

(Zip Code)

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Exhibit

No.

Description

99.1

Relevant slides from presentation by the Company on January 9, 2018.

ALKERMES PLC

Date: January 9, 2018

By:  

/s/ David J. Gaffin

David J. Gaffin

Senior Vice President, Chief Legal Officer

Great Science Deep Compassion Real Impact JANUARY 9, 2018 Richard Pops Chief Executive Officer 36th Annual J.P. Morgan Healthcare Conference © 2018 Alkermes. All rights reserved. Alkermes* Patient inspired*

2 Forward-Looking Statements and Non-GAAP Financial Information Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning future financial and operating performance, business plans or prospects of the company; the continued growth of the long-acting injectable antipsychotic market and the company’s commercial products; improvements to and modernization of the treatment ecosystem for opioid dependence; the timing, funding, results and feasibility of product development activities; whether the studies conducted for ALKS 5461, ALKS 3831 and ALKS 8700 will meet FDA’s requirements for approval and the company’s expectations and timelines for regulatory action by the FDA relating to the NDA submissions for ALNCD and ALKS 5461; the potential financial benefits that may be achieved under the license and collaboration agreement between the company and Biogen; and the therapeutic value and commercial potential, including blockbuster status, of the company’s products. Although the company believes that such forward-looking statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to risks, assumptions and uncertainties. You are cautioned not to place undue reliance on the forward-looking statements contained herein. The factors that could cause actual results to differ are discussed in the Alkermes plc Annual Report on Form 10-K for the year ended Dec. 31, 2016 and Quarterly Reports on Form 10-Q for the quarters ended Mar. 31, 2017 and Sept. 30, 2017, under the heading “Item 1A. Risk Factors”, and in other subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov and on the company’s website at www.alkermes.com in the “Investors—SEC filings” section. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation. Non-GAAP Financial Measures This presentation includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income and non-GAAP net income per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Alkermes plc Current Reports on Form 8-K filed with the SEC on Oct. 26, 2017 and Nov. 27, 2017. Note Regarding Trademarks The company is the owner of various U.S. federal trademark registrations (®) and other trademarks (TM), including ARISTADA® and VIVITROL®. Any other trademarks referred to in this presentation are the property of their respective owners. Appearances of such other trademarks herein should not be construed as any indicator that their respective owners will not assert their rights thereto. © 2018 Alkermes. All rights reserved. Alkermes*

VIVITROL®: Expanding Accessibility, Awareness and Use 13 Accessibility: Developing state and local ecosystems that encompass access and reimbursement, policy and treatment providers Awareness: Educating healthcare providers, public health officials, policymakers and employers: Implementation of CARA1 and 21st Century Cures funding provide opportunity to modernize treatment system Expanding footprint of state programs: >560 programs in 40 states Use: Room for growth with <4% market share in opioid dependence Concentrated prescribing: Top 5 states represent ~50% of net sales VIVITROL Net Sales ($M) 43% CAGR 1. Comprehensive Addiction and Recovery Act * Reflects midpoint of 2017 guidance, provided in the Current Reports on Form 8-K filed with the SEC on Oct. 26, 2017 and Nov. 27, 2017 $0 $100 $200 $300 2011 2012 2013 2014 2015 2016 2017E* © 2018 Alkermes. All rights reserved. Alkermes*

Expanding differentiating features and data to drive broad uptake ALNCD initiation product PDUFA date of June 30, 2018 Study comparing ARISTADA and INVEGA SUSTENNA® initiated Q4 2017 Expanding commercial presence in hospital setting in 2018 Collaborating with policymakers and industry peers to improve treatment system for serious mental illness Annual growth 99%* compared to 2016 17 ARISTADA®: Gaining Traction in the Long-Acting Atypical Antipsychotic Market *Reflects midpoint of Q4 2017 guidance, provided on Q3 2017 financial results conference call on Oct. 26, 2017 $0 $5 $10 $15 $20 $25 $30 ARISTADA Net Sales ($M) Q4’15 Q1’16 Q2’16 Q3’16 Q4’16 Q1’17 Q2’17 Q3’17 Q4’17E* © 2018 Alkermes. All rights reserved. Alkermes*

Growing business with significant revenues and operational leverage Revenue growth driven by proprietary commercial products Base business with potential to grow to >$2B into 2020s Next phase of growth identified with late-stage pipeline assets Strong balance sheet with >$560M cash & investments (as of 9/30/17) 30 Strong Organization Built for Scale (in millions, except per share amounts) 2017 Select Financial Expectations† Revenues $870 – 900 GAAP Net Loss $(140) – (170) Non-GAAP Net Income‡ $5 – 35 GAAP Loss Per Share $(0.91) – (1.10) Non-GAAP Net Income Per Share (Diluted) $0.03 – 0.22 † This financial guidance, provided by Alkermes plc in its Current Report on Form 8-K filed with the SEC on Nov. 27, 2017, is effective only as of such date. The company expressly disclaims any obligation to update or reaffirm guidance, and this presentation is not a reaffirmation or update of previously provided historical guidance. The company only provides guidance in a Regulation FD compliant manner. ‡ Non-GAAP net income adjusts for one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; certain other one-time or non-cash items; and the income tax effect of these reconciling items. © 2018 Alkermes. All rights reserved. Alkermes*